Intensity Therapeutics, Inc.

59 articles about Intensity Therapeutics, Inc.

• 

  On the Road to ASCO: Preview Some Key Presentations

  6/2/2021

  BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.

•  Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/20/2021

    Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer

  3/24/2021

  Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company developing proprietary, intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced that following receipt of the authorization from Health Canada, Intensity executed agreements with The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized

• Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411)

  11/11/2020

  Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced new efficacy and safety data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate.

• Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study

  9/17/2020

  Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of the cancer, today announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Yervoy® (ipilimumab), Bristol Myers Squibb’s (BMS) Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4)

• Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 Studies

  9/9/2020

  Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patients have been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy in Phase 2, KEYNO

• Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity

  6/25/2020

  Intensity Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results from the Company’s nonclinical research in the International Journal of Molecular Sciences (IJ

• Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020

  5/20/2020

  Presentation reports safety and efficacy results of INT230-6 administered alone and in combination with pembrolizumab (Keynote A10 study); safety of combination was comparable to INT230-6 monotherapy Following dosing INT230-6 alone, 13 patients had stable disease for greater than 6 months and 10 subjects had regression of uninjected tumors (abscopal effects) WESTPORT, Conn.--( BUSINESS WIRE )-- Intensity Therapeutics, Inc. , a clinical-stage

• Portage provides update on portfolio company, Intensity Therapeutics, Inc.

  4/15/2020

  Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a portfolio company, Intensity Therapeutics, Inc. ("Intensity"). Portage Biotech Inc. holds an 9.7% equity interest in Intensity. Intensity signs clinical trial collaboration with Bristol Mye

• Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors

  4/14/2020

  Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.

• Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®

  3/30/2020

  Phase 2 cohorts evaluating the combination in patients with pancreatic cancer, cholangiocarcinoma, and microsatellite stable colorectal cancer to begin enrollment

• Intensity Therapeutics to Participate in East/West CEO Conference

  1/8/2020

  Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that Lewis H. Bender, President and CEO, will be a featured panelist on the “Developments in The Oncology Landscape” panel at East/West CEO.

• Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®

  10/31/2019

  Intensity Therapeutics, Inc. announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda®, Merck’s anti-PD-1 therapy.

• Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference

  10/22/2019

  Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected for a podium presentation at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting, taking place November 6-10, 2019, in National Harbor, MD.

• Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

  7/17/2019

  INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer

• Intensity Therapeutics Announces Clinical Collaboration with Merck

  6/25/2019

  Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types

• Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019

  6/1/2019

  Intensity Therapeutics, Inc. announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

• Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

  5/16/2019

  Intensity Therapeutics, Inc. announced that a poster highlighting the safety profile, tumor regression activity and immune activation of the company’s lead product candidate, INT230-6, will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2019 in Chicago.

• Intensity Therapeutics Raises $6.5 Million in Series B Financing

  11/2/2018

  Proceeds to enable advancement of lead product candidate INT230-6 into Phase 2 clinical development for solid tumors